Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RXFP1 | Q9HBX9 | 13/20 | 0.47 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.41 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.40 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | AURKA | O14965 | 1/20 | 0.37 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.37 |
| ▸ | TAS2R14 | Q9NYV8 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22556334 | 0.82 | RXFP1 (0.53) | RXFP1MAPK8ABCG2SMN1; SMN2MEN1 | |
| SCHEMBL22556321 | 0.80 | RXFP1 (0.53) | RXFP1MAPK8ABCG2PTGS1SMN1; SMN2 | |
| SCHEMBL23713153 | 0.78 | RXFP1 (0.49) | RXFP1MAPK8ABCG2PTGS1SMN1; SMN2 | |
| SCHEMBL22571443 | 0.77 | GAA (0.57) | RXFP1SMN1; SMN2MEN1POLBKMT2A | |
| SCHEMBL23713115 | 0.75 | RXFP1 (0.42) | RXFP1MAPK8ABCG2PTGS1SMN1; SMN2 | |
| SCHEMBL22556325 | 0.74 | RXFP1 (0.50) | RXFP1MAPK8ABCG2PTGS1SMN1; SMN2 | |
| SCHEMBL22556312 | 0.74 | RXFP1 (0.50) | RXFP1MAPK8ABCG2PTGS1SMN1; SMN2 | |
| SCHEMBL25541393 | 0.73 | RXFP1 (0.44) | RXFP1MAPK8ABCG2TAS2R14 | |
| SCHEMBL25543231 | 0.73 | MEN1 (0.44) | RXFP1MAPK8SMN1; SMN2MEN1POLB | |
| SCHEMBL22556346 | 0.73 | RXFP1 (0.48) | RXFP1MAPK8ABCG2PTGS1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210238154-A1 | OXADIAZOLE COMPOUNDS | VIVACE THERAPEUTICS, INC. | 2021-08-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210238154-A1 | OXADIAZOLE COMPOUNDS | YAP1, TEAD2, TEAD3 | RXFP1 3511/4885MAPK8 986/4885ABCG2 2985/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.